AZD1222
E1423948
UNEXPLORED
AZD1222 is the adenoviral vector-based COVID-19 vaccine developed by the University of Oxford and AstraZeneca for the prevention of SARS-CoV-2 infection.
All labels observed (1)
| Label | Occurrences |
|---|---|
| AZD1222 canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T20301386 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: AZD1222 Context triple: [Vaxzevria COVID-19 vaccine, hasAlternativeName, AZD1222]
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: AZD1222 Target entity description: AZD1222 is the adenoviral vector-based COVID-19 vaccine developed by the University of Oxford and AstraZeneca for the prevention of SARS-CoV-2 infection.
-
A.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
B.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
E.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.